< Back to previous page

Project

Metabolic Balance Studies in Short Bowel Syndrome with Colon-in-Continuity

The project aims at investigating novel treatment strategies for patients suffering from short bowel syndrome with colon-in-continuity. Previous studies have shown that a glucagon-like peptide-2 (GLP-2) analog, teduglutide, promotes the growth of the intestinal villi in subjects with short bowel syndrome without a remaining colon and decreased the need for intravenous nutritional support. The impact of this drug was also investigated in patients with short bowel syndrome with colon-in-continuity. However, compared to the results obtained in subjects without a remaining colon, the duration of the studies in subjects with colon-in-continuity was too short to assess the effect of the teduglutide. Therefore, we will perform metabolic balance studies to investigate the outcome of a new, long-acting GLP-2 analog apraglutide in short bowel syndrome patients with colon-in-continuity. Additionally, we will investigate other aspects, such as alternative mechanisms of action of GLP-2 analogs (motility, microbiota, intestinal permeability), quality of life and complications of short bowel syndrome.

Date:16 Apr 2020 →  Today
Keywords:Glucagon-like peptide-2, Metabolic Balance Studies, Short Bowel Syndrome, Colon-in-Continuity
Disciplines:Gastro-enterology
Project type:PhD project